Rationale and protocol for a safety, tolerability and feasibility randomized, parallel group, double-blind, placebo-controlled, pilot study of a novel ketone ester targeting frailty via immunometabolic geroscience mechanisms.

Autor:	Stubbs BJ; Buck Institute for Research on Aging, Novato, CA, USA., Alvarez-Azanedo G; Buck Institute for Research on Aging, Novato, CA, USA., Peralta S; Buck Institute for Research on Aging, Novato, CA, USA., Roa-Diaz S; Buck Institute for Research on Aging, Novato, CA, USA., Gray W; Buck Institute for Research on Aging, Novato, CA, USA., Alexander L; Buck Institute for Research on Aging, Novato, CA, USA., Silverman-Martin W; Buck Institute for Research on Aging, Novato, CA, USA., Garcia T; Buck Institute for Research on Aging, Novato, CA, USA., Blonquist TM; Biofortis, Mérieux NutriSciences, Addison, IL, United States., Upadhyay V; Department of Microbiology & Immunology, UCSF, San Francisco, CA, USA 94143.; Department of Medicine, UCSF, San Francisco California, USA., Turnbaugh PJ; Department of Microbiology & Immunology, UCSF, San Francisco, CA, USA 94143.; Chan Zuckerberg Biohub-San Francisco, San Francisco, CA, USA 94158., Johnson JB; Independent Researcher, Greenbrae, CA, USA., Newman JC; Buck Institute for Research on Aging, Novato, CA, USA.; Division of Geriatrics, UCSF, San Francisco, California, USA.
Jazyk:	angličtina
Zdroj:	MedRxiv : the preprint server for health sciences [medRxiv] 2023 Oct 26. Date of Electronic Publication: 2023 Oct 26.
DOI:	10.1101/2023.10.25.23297571
Abstrakt:	Background: Frailty is a geriatric syndrome characterized by chronic inflammation and metabolic insufficiency that creates vulnerability to poor outcomes with aging. We hypothesize that geroscience interventions, which target mechanisms of aging, could ameliorate frailty. Metabolites such as ketone bodies are candidate geroscience interventions, having pleiotropic effects on inflammo-metabolic aging mechanisms. Ketone esters (KEs) induce ketosis without dietary changes, but KEs have not been studied in an older adult population. Our long-term goal is to examine if KEs modulate geroscience mechanisms and clinical outcomes relevant to frailty in older adults. Objectives: The primary objective of this randomized, placebo-controlled, double-blinded, parallel-group, pilot trial is to determine tolerability of 12-weeks of KE ingestion in a generalizable population of older adults (≥ 65 years). Secondary outcomes include safety and acute blood ketone kinetics. Exploratory outcomes include physical function, cognitive function, quality of life, aging biomarkers and inflammatory measures. Methods: Community-dwelling adults who are independent in activities of daily living, with no unstable acute medical conditions (n=30) will be recruited. The study intervention is a KE or a taste, appearance, and calorie matched placebo beverage. Initially, acute 4-hour ketone kinetics after 12.5g or 25g of KE consumption will be assessed. After collection of baseline safety, functional, and biological measurements, subjects will randomly be allocated to consume KE 25g or placebo once daily for 12-weeks. Questionnaires will assess tolerability daily for 2-weeks, and then via phone interview at bi-monthly intervals. Safety assessments will be repeated at week 4. All measures will be repeated at week 12. Conclusion: This study will evaluate feasibility, tolerability, and safety of KE consumption in older adults and provide exploratory data across a range of geroscience-related endpoints. This data will inform design of larger trials to rigorously test KE effects on geroscience mechanisms and clinical outcomes relevant to frailty. Competing Interests: Author Declarations and Conflict Management: The principal investigator (Dr. Newman), Dr. Brianna Stubbs, and the Buck Institute hold shares in BHB Therapeutics. Drs. Newman and Stubbs are inventors on patents relating to the use of ketone bodies that are assigned to The Buck Institute. All other authors have no conflicts to declare. Individual and institutional extensive conflict management plans were developed and approved by the Buck Institute and the IRB. Actions and decisions important to subject safety and study integrity are carried out by parties with no potential financial conflict. Participant consent is obtained by licensed registered nurses who have no financial conflict. Decisions on subject enrollment, continuation, and discontinuation are made by independent medical officers unaffiliated with Buck Institute and with no financial conflict. Data analysis for the primary outcome is carried out by an independent statistician with no financial conflict. Study staff, including the principal investigator, will maintain blinding through study completion unless unblinding is required for safety concerns.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu